Liver Enzyme-Lowering Drugs Market Report – Research, Industry Analysis Reports and Market Demands

Global Liver Enzyme-Lowering Drugs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Liver Enzyme-Lowering Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Chemical Enzyme Reducers (Rapid Onset, 1-2 weeks)
- 1.3.3 Anti‑inflammatory Glycyrrhizic Acid Preparations (Moderate Onset, 2-4 weeks)
- 1.3.4 Detoxifying Enzyme Reducers (Indirect, variable)
- 1.3.5 Herbal Extracts (Antioxidant, 2-4 weeks)
- 1.3.6 TCM Enzyme Reducers (Rapid to Moderate)
- 1.3.7 MASH‑Targeted New Drugs (Slow, long‑term)
1.4 Market Analysis by Administration
- 1.4.1 Overview: Global Liver Enzyme-Lowering Drugs Consumption Value by Administration: 2021 Versus 2025 Versus 2032
- 1.4.2 Oral
- 1.4.3 Intravenous
1.5 Market Analysis by Application
- 1.5.1 Overview: Global Liver Enzyme-Lowering Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.5.2 Pre‑Exam Health Check Normalization
- 1.5.3 Acute Hepatitis Flare
- 1.5.4 Chronic Hepatitis Maintenance
- 1.5.5 MASH/NASH Treatment
- 1.5.6 Adjunct to Antiviral Therapy
- 1.5.7 Others
1.6 Global Liver Enzyme-Lowering Drugs Market Size & Forecast
- 1.6.1 Global Liver Enzyme-Lowering Drugs Consumption Value (2021 & 2025 & 2032)
- 1.6.2 Global Liver Enzyme-Lowering Drugs Sales Quantity (2021-2032)
- 1.6.3 Global Liver Enzyme-Lowering Drugs Average Price (2021-2032)

2 Manufacturers Profiles

3 Competitive Environment: Liver Enzyme-Lowering Drugs by Manufacturer

3.1 Global Liver Enzyme-Lowering Drugs Sales Quantity by Manufacturer (2021-2026)
3.2 Global Liver Enzyme-Lowering Drugs Revenue by Manufacturer (2021-2026)
3.3 Global Liver Enzyme-Lowering Drugs Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Liver Enzyme-Lowering Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Liver Enzyme-Lowering Drugs Manufacturer Market Share in 2025
- 3.4.3 Top 6 Liver Enzyme-Lowering Drugs Manufacturer Market Share in 2025
3.5 Liver Enzyme-Lowering Drugs Market: Overall Company Footprint Analysis
- 3.5.1 Liver Enzyme-Lowering Drugs Market: Region Footprint
- 3.5.2 Liver Enzyme-Lowering Drugs Market: Company Product Type Footprint
- 3.5.3 Liver Enzyme-Lowering Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Liver Enzyme-Lowering Drugs Market Size by Region
- 4.1.1 Global Liver Enzyme-Lowering Drugs Sales Quantity by Region (2021-2032)
- 4.1.2 Global Liver Enzyme-Lowering Drugs Consumption Value by Region (2021-2032)
- 4.1.3 Global Liver Enzyme-Lowering Drugs Average Price by Region (2021-2032)
4.2 North America Liver Enzyme-Lowering Drugs Consumption Value (2021-2032)
4.3 Europe Liver Enzyme-Lowering Drugs Consumption Value (2021-2032)
4.4 Asia-Pacific Liver Enzyme-Lowering Drugs Consumption Value (2021-2032)
4.5 South America Liver Enzyme-Lowering Drugs Consumption Value (2021-2032)
4.6 Middle East & Africa Liver Enzyme-Lowering Drugs Consumption Value (2021-2032)

5 Market Segment by Type

5.1 Global Liver Enzyme-Lowering Drugs Sales Quantity by Type (2021-2032)
5.2 Global Liver Enzyme-Lowering Drugs Consumption Value by Type (2021-2032)
5.3 Global Liver Enzyme-Lowering Drugs Average Price by Type (2021-2032)

6 Market Segment by Application

6.1 Global Liver Enzyme-Lowering Drugs Sales Quantity by Application (2021-2032)
6.2 Global Liver Enzyme-Lowering Drugs Consumption Value by Application (2021-2032)
6.3 Global Liver Enzyme-Lowering Drugs Average Price by Application (2021-2032)

7 North America

7.1 North America Liver Enzyme-Lowering Drugs Sales Quantity by Type (2021-2032)
7.2 North America Liver Enzyme-Lowering Drugs Sales Quantity by Application (2021-2032)
7.3 North America Liver Enzyme-Lowering Drugs Market Size by Country
- 7.3.1 North America Liver Enzyme-Lowering Drugs Sales Quantity by Country (2021-2032)
- 7.3.2 North America Liver Enzyme-Lowering Drugs Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

8.1 Europe Liver Enzyme-Lowering Drugs Sales Quantity by Type (2021-2032)
8.2 Europe Liver Enzyme-Lowering Drugs Sales Quantity by Application (2021-2032)
8.3 Europe Liver Enzyme-Lowering Drugs Market Size by Country
- 8.3.1 Europe Liver Enzyme-Lowering Drugs Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Liver Enzyme-Lowering Drugs Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

9.1 Asia-Pacific Liver Enzyme-Lowering Drugs Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Liver Enzyme-Lowering Drugs Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Liver Enzyme-Lowering Drugs Market Size by Region
- 9.3.1 Asia-Pacific Liver Enzyme-Lowering Drugs Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Liver Enzyme-Lowering Drugs Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

10.1 South America Liver Enzyme-Lowering Drugs Sales Quantity by Type (2021-2032)
10.2 South America Liver Enzyme-Lowering Drugs Sales Quantity by Application (2021-2032)
10.3 South America Liver Enzyme-Lowering Drugs Market Size by Country
- 10.3.1 South America Liver Enzyme-Lowering Drugs Sales Quantity by Country (2021-2032)
- 10.3.2 South America Liver Enzyme-Lowering Drugs Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

11.1 Middle East & Africa Liver Enzyme-Lowering Drugs Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Liver Enzyme-Lowering Drugs Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Liver Enzyme-Lowering Drugs Market Size by Country
- 11.3.1 Middle East & Africa Liver Enzyme-Lowering Drugs Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Liver Enzyme-Lowering Drugs Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

12.1 Liver Enzyme-Lowering Drugs Market Drivers
12.2 Liver Enzyme-Lowering Drugs Market Restraints
12.3 Liver Enzyme-Lowering Drugs Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Liver Enzyme-Lowering Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Liver Enzyme-Lowering Drugs
13.3 Liver Enzyme-Lowering Drugs Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Liver Enzyme-Lowering Drugs Typical Distributors
14.3 Liver Enzyme-Lowering Drugs Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Liver Enzyme-Lowering Drugs market size was valued at US$ 9274 million in 2025 and is forecast to a readjusted size of US$ 23999 million by 2032 with a CAGR of 14.5% during review period.
Liver Enzyme-Lowering Drugs refer to a class of liver disease therapeutics that target the reduction of serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels as the primary clinical endpoint, distinct from hepatoprotective drugs which aim to improve overall liver function, promote hepatocyte regeneration, and enhance liver detoxification. Enzyme-lowering drugs include: chemical enzyme reducers such as bifendate and bicyclol; anti-inflammatory enzyme reducers such as glycyrrhizic acid preparations; detoxifying enzyme reducers such as glutathione and tiopronin; herbal extracts such as silymarin and silibinin; and proprietary Chinese medicines such as Pien Tze Huang, Hugan Tablets, and Wuzhi Tablets. In recent years, novel MASH/NASH-targeted drugs (e.g., Resmetirom, efruxifermin) also aim to reduce ALT levels as a core endpoint, representing an upgrade from symptomatic management to disease-modifying therapy.
Metamaterial stealth skin is a “game changer” in military stealth technology. Unlike traditional coatings that rely on material absorption, metamaterials use artificially designed subwavelength structures to actively guide electromagnetic waves “around” the target, reducing radar cross section by orders of magnitude. This paradigm shift breaks the thickness‑weight trade‑off of conventional absorbers, enabling wider bandwidth, higher gain, and multifunctional integration (stealth, load‑bearing, sensing, thermal management). Pricing: Due to high barriers in simulation, micro‑nano fabrication, and environmental validation, metamaterial skin costs significantly more than traditional coatings. Kuang‑Chi signed RMB 3.485 billion in new contracts in 2025 for its 4th‑generation metamaterial aviation structural parts (J‑20, J‑35). Overseas, F‑35 metamaterial skin is integrated by Lockheed Martin, Raytheon, etc., with cost absorbed into total airframe. Margins diverge: Chinese leaders (Kuang‑Chi, Jiacchi, Huaqin) enjoy 40–60% gross margins due to technology monopoly and military barriers; overseas primes bundle stealth into platform pricing. Downstream primary applications are dominated by combat aircraft (fighters, UCAVs, bombers), followed by naval, missile, and ground platforms. Incremental demand comes from: (1) fielding of 5th/6th generation fighters; (2) retrofitting legacy platforms (F‑16, F‑15, J‑10) with metamaterial patches; (3) low‑cost stealth skins for missiles and drones. Upstream‑downstream structure is short and closed: upstream – simulation software, precision fabrication tools, specialty materials; midstream – integrated manufacturers (Kuang‑Chi, Jiacchi, Huaqin, Lockheed Martin, BAE, etc.); downstream – prime contractors and defense ministries. Certification barriers are extremely high – years of live‑fire and environmental testing, plus structural integration requires aerodynamic and strength revalidation. Landscape is “China‑US duopoly plus European & allied followers”. China’s Kuang‑Chi is the absolute leader with 4th‑gen structural parts in mass production; Jiacchi and Huaqin complement in coatings and high‑temperature materials. US primes (Lockheed Martin, Raytheon, Northrop Grumman) embed metamaterials into F‑35, B‑21. European and Asian players (BAE, Leonardo, Dassault, Saab, LIG Nex1, Mitsubishi Heavy) follow their national 5th‑gen or naval programs. Startups in Israel, Germany, India (FVMat, FibreCoat, Meta Tattva) are at lab or pilot stage. Uncertainties include: (1) yield and cost control in mass production (Kuang‑Chi’s 97.51% yield is industry‑leading, but others lag); (2) multispectral compatibility (radar+IR+visible) and 6th‑gen requirements; (3) export controls on raw materials and precision equipment; (4) whether civilian metamaterial scaling (EMI shielding, antennas) could back‑penetrate military use. Conclusion: Metamaterial stealth skin marks the transition from coating‑based to structurally integrated stealth. Core driver is the rigid demand for ultra‑wideband, multispectral, lightweight stealth in 5th/6th generation aircraft. Structural features are extreme technical barriers, long certification cycles, closed supply chains, and sustained moats for first movers. Over the next decade, the global market will further concentrate on Chinese and US core suppliers, while European/Asian players maintain niche competitiveness in specific bands or naval platforms.In the liver enzyme-lowering drug market, the real driver of multi-billion-dollar scale is not novel MASH therapies, but the hidden “rapid normalization” demand from pre‑exam health checks. Pricing: rapid‑onset oral drugs such as bifendate, bicyclol, and Wuzhi tablets cost only RMB 2-5 per day, far below glycyrrhizic acid preparations (RMB 10-20) and silymarin (RMB 8-15), and even farther below MASH-targeted drugs (tens of thousands USD/year). Margins: generic bifendate/bicyclol have gross margins of only 20-30% due to intense competition; Wuzhi tablets (proprietary) achieve 50-60%; glycyrrhizic acid preparations 40-50%; silymarin 35-45%. In retail channels for pre‑exam “emergency lowering”, TCM products like Wuzhi and Hugan tablets enjoy even higher margins (60-70%), with cost focused on channel promotion and consumer education. Downstream primary applications: “pre‑exam rapid normalization” accounts for >40% of rapid‑onset enzyme-lowering consumption, concentrated in employment, insurance, and military medical exams; acute hepatitis flare 20%; chronic hepatitis maintenance 25%; others include antiviral adjunct and MASH management. Incremental demand comes from: (1) rising health check penetration (over 600 million exams in China in 2025), with 10-15% showing elevated ALT/AST; (2) expanding NAFLD population (>200 million); (3) e‑commerce and O2O platforms making rapid‑onset drugs a “stock‑up necessity”. Upstream‑downstream structure is short: upstream API and intermediates (Liaoning Panjin Green, Zhejiang Medicine); midstream formulators (Beijing Union Pharmaceutical, Sichuan Hezheng, Zibo Xinda); downstream hospital pharmacies, retail drugstores, and e‑commerce platforms. Seasonal peaks (March-April, September-October) see 2-3x normal sales. Landscape: stable structure of “one originator + multiple generics + one proprietary TCM” in rapid‑onset segment. Beijing Union Pharmaceutical holds originator status for bifendate and bicyclol, strongest in prescription channel. Sichuan Hezheng’s Wuzhi tablets dominate retail and e‑commerce due to exclusivity, rapid action, and no prescription requirement. Zibo Xinda, Zhejiang Medicine compete on price in primary care. Glycyrrhizic acid segment led by Chia Tai Tianqing; silymarin by Madaus and Tasly. MASH new drugs (Madrigal, 89bio, Akero) are expensive, require long‑term use, and do not overlap with “rapid normalization” scenarios – they will not disrupt traditional market in the short term. Uncertainties include: (1) “rebound phenomenon” of bifendate/bicyclol raising concerns, potentially replaced by safer alternatives; (2) generic risk for Wuzhi tablets if same‑name same‑formulation policy changes; (3) changes in medical exam standards (e.g., removal of ALT/AST as hard indicator) would directly impact demand; (4) tighter e‑commerce regulation on prescription drug sales. Conclusion: The most dynamic, fastest‑growing sub‑segment in liver enzyme-lowering drugs is not innovative targeted therapies, but the hidden “exam economy” driven rapid‑onset market. Core drivers are workplace health check prevalence and “anxiety to normalize” among those with elevated enzymes. Structural features are rapid onset, low price, pulsed consumption, and channel dominance. Over the next 3-5 years, companies that master retail and online channels (e.g., Sichuan Hezheng, Sunflower Pharmaceutical) will capture the largest incremental growth, while prescription‑channel leaders (Beijing Union Pharmaceutical) will maintain a stable hospital presence.
This report is a detailed and comprehensive analysis for global Liver Enzyme-Lowering Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Liver Enzyme-Lowering Drugs market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Liver Enzyme-Lowering Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Liver Enzyme-Lowering Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Liver Enzyme-Lowering Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Liver Enzyme-Lowering Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Liver Enzyme-Lowering Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Beijing Union Pharmaceutical Factory, Sichuan Hezheng Pharmaceutical, Zibo Xinda Pharmaceutical, Liaoning Panjin Green Pharmaceutical, Zhejiang Medicine, Minophagen Pharmaceutical, Chia Tai Tianqing Pharmaceutical, Madaus GmbH, Tasly Pharmaceutical, China Resources Shuanghe, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Liver Enzyme-Lowering Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chemical Enzyme Reducers (Rapid Onset, 1-2 weeks)
Anti‑inflammatory Glycyrrhizic Acid Preparations (Moderate Onset, 2-4 weeks)
Detoxifying Enzyme Reducers (Indirect, variable)
Herbal Extracts (Antioxidant, 2-4 weeks)
TCM Enzyme Reducers (Rapid to Moderate)
MASH‑Targeted New Drugs (Slow, long‑term)
Market segment by Administration
Oral
Intravenous
Market segment by Application
Pre‑Exam Health Check Normalization
Acute Hepatitis Flare
Chronic Hepatitis Maintenance
MASH/NASH Treatment
Adjunct to Antiviral Therapy
Others
Major players covered
Beijing Union Pharmaceutical Factory
Sichuan Hezheng Pharmaceutical
Zibo Xinda Pharmaceutical
Liaoning Panjin Green Pharmaceutical
Zhejiang Medicine
Minophagen Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Madaus GmbH
Tasly Pharmaceutical
China Resources Shuanghe
Chongqing Yaoyou Pharmaceutical
Zhangzhou Pien Tze Huang Pharmaceutical
Heilongjiang Sunflower Pharmaceutical
Anhui Jiren Pharmaceutical
Hunan Warner Pharmaceutical
Madrigal Pharmaceuticals
89bio
Akero Therapeutics
Seishin Chemical
Meda Pharma (Spain)
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Liver Enzyme-Lowering Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Liver Enzyme-Lowering Drugs, with price, sales quantity, revenue, and global market share of Liver Enzyme-Lowering Drugs from 2021 to 2026.
Chapter 3, the Liver Enzyme-Lowering Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Liver Enzyme-Lowering Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Liver Enzyme-Lowering Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Liver Enzyme-Lowering Drugs.
Chapter 14 and 15, to describe Liver Enzyme-Lowering Drugs sales channel, distributors, customers, research findings and conclusion.

Buy now